Description

Oral semaglutide is a GLP-1 receptor agonist. FDA-approved Rybelsus is available in 3 mg, 7 mg and 14 mg strengths. The correct strength depends on where a patient is in the labeled treatment regimen and their clinician’s assessment.

What are Semaglutide 7 mg Tablets?
Semaglutide 7 mg is an oral GLP-1 receptor agonist strength. In the FDA-approved Rybelsus 3 mg / 7 mg / 14 mg regimen, 7 mg is used after the first 30 days at 3 mg. It can be maintained when additional glycemic control is not needed, subject to clinician guidance.

How Semaglutide 7 mg Works
Semaglutide activates GLP-1 receptors and has glucose-dependent effects on insulin and glucagon. It also delays gastric emptying and can influence appetite and satiety.

Where 7 mg Fits in the FDA-Approved Rybelsus Regimen
For Rybelsus 3 mg / 7 mg / 14 mg, the labeled schedule starts with 3 mg once daily for 30 days, then increases to 7 mg once daily. On Day 61 or later, 7 mg may be maintained if no additional glycemic control is needed, or the clinician may increase to 14 mg if additional glycemic control is needed.

Administration of FDA-Approved Rybelsus
The current U.S. label directs patients to take the tablet once daily on an empty stomach in the morning with up to 4 ounces of water, swallow it whole, and wait at least 30 minutes before food, other beverages or other oral medicines. These directions are product-specific.

Not Interchangeable Milligram-for-Milligram
FDA labeling states that different oral semaglutide tablet formulations are not substitutable on a mg-to-mg basis. A product page should therefore identify the actual formulation accurately and avoid implying equivalence without evidence.

Important Safety Information
Semaglutide is a GLP-1 receptor agonist and is not appropriate for every patient. Approved semaglutide products carry important warnings and contraindications. A healthcare professional should review the patient’s medical history, current medicines and treatment goals before use.

Common adverse reactions reported with approved semaglutide products are mainly gastrointestinal and can include nausea, vomiting, diarrhea, abdominal pain and constipation. Serious reactions can also occur, including pancreatitis, gallbladder problems, kidney injury related to volume depletion, severe gastrointestinal reactions, hypersensitivity reactions and complications of diabetic retinopathy in some patients.

Approved semaglutide labeling includes a boxed warning concerning the risk of thyroid C-cell tumors observed in rodents. Semaglutide products are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The relevance of the rodent findings to humans has not been established.

Tell your healthcare professional about planned surgery or procedures requiring general anesthesia or deep sedation, and discuss pregnancy or plans for pregnancy. This summary is not a substitute for the complete prescribing information for the exact product supplied.

Who Should Speak With a Healthcare Professional Before Use?

• Anyone considering semaglutide should have the exact product, indication and dose assessed by a qualified healthcare professional.
• Discuss a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, previous pancreatitis, gallbladder disease, kidney problems, severe gastrointestinal disease, diabetic retinopathy and serious allergies.
• Tell the prescriber about insulin, sulfonylureas and other medicines that can affect blood glucose, as well as other oral medicines when using oral semaglutide.
• Discuss pregnancy, plans for pregnancy or breastfeeding before treatment. Current FDA labeling advises discontinuation of semaglutide at least 2 months before a planned pregnancy because of its long washout period.
• Tell healthcare providers about semaglutide before planned surgery or deep sedation because GLP-1 receptor agonists delay gastric emptying and pulmonary aspiration has been reported.

The information on this page is provided for general educational and product-information purposes and is not medical advice, diagnosis or a substitute for the prescribing information supplied with the medication. Semaglutide is a prescription medicine and may not be appropriate for everyone. Always follow the exact product label and instructions from a licensed healthcare professional. Seek urgent medical care for a suspected medical emergency.